Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPM001 in progressive hepatocellular carcinoma
NCT05536427Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IPM001 in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Safety (AE/ irAE/ SAE) at 12 months and Tolerance (DLT/ MTD/ OBD) at 12 months. Status: unknown.
02
Drugs
IPM001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05536427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536427.